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Abstract
Diabetes mellitus is now recognized as a societal disease that significantly burden health care systems in highly developed as well as develop-
ing countries and constitutes a serious problem of public health world-wide. The aim of this study was to estimate the value of reimbursement of 
diabetes-related drugs in 2012 and 2013 and to analyze indirect costs generated by diabetes in Poland in 2012. It was revealed that reimbursement 
of glucose test strips, antidiabetic drugs and insulins covered by the National Health Fund was as high as 1.3 billion PLN in 2012 and 1.5 billion 
PLN in 2013 and the dominant cost drivers were glucose test strips (49% of costs in 2012 and 52% of costs in 2013) and insulins (40% and 38% of 
total reimbursement costs due to diabetes, respectively). Total indirect costs of diabetes type 1 and type 2 in 2012 were as high as 59 million PLN 
and 66.5 million PLN and absenteeism due to sick leave was a main cost driver (61% in diabetes type 1 and 95% in diabetes type 2, respectively). 
In summary, costs associated with diabetes constitute a serious burden for the National Health Fund as well as for the Social Insurance Institution 
in Poland. 
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Introduction
Diabetes mellitus belongs to a group of metabolic 
diseases characterized by hyperglycemia caused by dis-
orders in insulin secretion or by its effects. Currently, 
diabetes mellitus is regarded as a societal disease which 
puts a significant strain on the health care system in 
the developed as well as the developing countries and 
constitutes a serious problem for public health world-
wide [1]. According to data for 2014 provided by the 
International Diabetes Federation – IDF, the number of 
persons with diabetes  worldwide amounted to around 
387 million [2]. In Poland, it is estimated that the num-
ber of person with diabetes in 2013 was about two mil-
lion, with the diabetes type 1 morbidity rate for Poland 
of 0.3% (incidence of 10.2/100 thousand of cases per 
year), while the prevalence of diabetes type 2 oscillates 
between 1.6–4.7% (incidence of about 200/100 thou-
sand cases per year) [1]. As a result of its considerable 
incidence, the morbidity and economic consequences, 
diabetes mellitus has become the subject of many epi-
demiologic studies and cost analyses of the disease and 
it also creates a significant problem for public health in 
its broad context.
Within the framework of cost analysis connected with 
different diseases, we can identify the following cost 
groups: direct costs, indirect costs and intangible costs. 
Direct costs can be split into medical costs (expenses re-
lating to the purchase of medical equipment, medication, 
salaries of medical staff, diagnostics and hospital stay) 
and non-medical costs (e.g. connected with third-party 
care provided to patients, the cost of transportation of pa-
tients, adjusting patients’ accommodation to their needs 
or special diets) [3]. By indirect costs we understand the 
value of lost production resulting from absenteeism, dis-
ability (disability benefits) and premature deaths of peo-
ple of working age, which generates specific productivity 
losses [3]. 
One particularly significant aspect associated with 
the measurement of indirect costs is the implementation 
of an appropriate method of assessment of the costs of 
lost production (valuation of lost time). The main meth-
ods assessing the cost of the lost production comprise the 
following: friction cost method – FCM, human capital 
Przygotowanie i edycja anglojęzycznych wersji publikacji finansowane w ramach umowy 914/P-DUN/2016 
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approach – HCA and health state valuation; the least fre-
quently used approach in practice [3]. 
Human capital approach is the most popular and the 
most frequently used method assessing indirect costs. 
As a result of the disease prevalence, the capital at the 
disposal of a unit cannot be used to the full. The conse-
quence of such an approach is that indirect costs occur as 
long as the human capital potential is limited [4]. Indirect 
costs are estimated by the HCA method as the product 
of the length of a disease (i.e. the time when human 
capital is not utilized) and productivity of an employee 
per unit of time (productivity of human capital) to the 
effect that the estimated value corresponds with theoreti-
cal, potential loss of productivity. A pure, classical HCA 
method assumes the lack of system unemployment and 
full maximum work efficiency when no health problems 
take place. In friction cost method, on the other hand, 
costs associated with a disease are analyzed from the 
point of view of a company (the assessment concerns the 
real loss of productivity), and in the FCM approach it 
is requested that the assessment of the long-term effect 
of an employee’s sickness should take into account the 
circumstances which could diminish the real loss of pro-
ductivity (an employee could be substituted by e.g. a new 
staff member) [3, 4].
In case an employee is forced to discontinue work, 
then indirect cost is equal to the volume of production 
which is lost because of an employees’ sick absence (the 
so-called absenteeism). The loss of productivity connect-
ed with the presenteeism takes place when an employee 
decides to undertake professional activities despite his/
her bad health condition and then their efficiency falls 
down due to illness [4].
One very important element in the analysis of costs of 
disease is the choice of an appropriate point of view from 
which the assessment of the cost of disease is made (i.e. 
the perspective). The perspective of a patient takes into 
account solely costs incurred directly by the patient him-
self omitting the costs incurred by the public payer (e.g. 
the National Health Fund). In turn, the perspective of 
a public payer takes into account the costs of reimburse-
ment from public funds omitting the costs incurred by the 
patient; there is also the perspective of a payer taking into 
account both the costs of the public payer and a patient. 
The social perspective reflects the broadest presentation 
of costs of the disease, which comprises all kinds of costs 
associated with an illness and its treatment, regardless of 
their source; hence it requires the consideration of not 
only economic consequences connected with the process 
of treatment and complications, but also it requires the 
consideration of indirect costs connected with the loss of 
productivity of a sick employee in the analysis [5]. 
Cost of illness studies make it possible to measure and 
identify costs of a particular disease entity. The studies 
also allow to assess the burden imposed on a given so-
ciety by an illness occurring in a given population [6]. 
This type of analysis comprises all sorts of costs which 
are connected, among others, with prevention, diagnostics 
and the course of treatment but they omit in their calcula-
tions health effects obtained from medical technologies 
data. At present, we can distinguish two main types of 
cost of disease analyses, which are dependent on the ac-
cepted analytical method: incidence-based cost of disease 
and prevalence-based cost of disease analysis [6–8]. 
The prevalence-based method assesses costs connect-
ed with a given disease entity within a year. This method 
is characterized by a simpler, analytical approach; there-
fore it is used much more often .
It is based on adding direct and indirect costs asso-
ciated with a given disease entity which were incurred 
in a given year in a group of patients with the analyzed 
disease. In turn, the prevalence-based method assesses 
costs associated with a given disease entity within the 
whole life-span of people who were diagnosed with the 
analyzed disease entity in a given period of time. In this 
method, patients are divided into groups on the basis of 
prevalence which will be under observation from the be-
ginning of an illness till the patient’s death in order to 
make an assessment of the total costs of the disease for 
each of these patients [6]. 
Diabetes mellitus treatment costs
1. Diabetes mellitus treatment costs world-wide
Diabetes mellitus is a disease which constitutes 
a huge epidemiological problem which translates into 
more and more serious economic consequences for indi-
vidual societies [9], [10]. According to International Dia-
betes Federation (IDF) report of 2013, it is estimated that 
the cost of diabetes treatment amounted to 548 billion 
UDS and constituted around 11% of the total costs in-
curred by healthcare world-wide (healthcare provided by 
healthcare institutions as well as individual care organ-
ized by patients themselves) [10]. The available research 
results also indicate that costs generated by diabetes are 
not evenly distributed in particular age groups and that 
the majority of costs (76%) are connected with diabetes 
treatment in adult population (50–79 years of age) [10]. 
Additional costs connected with undiagnosed diabetes 
complications are assessed from the perspective of a pay-
er and amount to 18 billion USD per year (2864 USD per 
capita in the USA) [11]. 
The analysis of expenses covering diabetes treatment 
per person with diabetes, depending on the economic 
situation of a country, implies that in countries of low 
and medium income only 20% of financial means is con-
nected with diabetes treatment (on average 356 USD per 
person with diabetes, 545 USD PPP1 – Purchasing Power 
Parity per person with diabetes). In turn, in countries of 
high income, the cost of diabetes per capita is estimated 
at 5621 USD [10]. In 2013, the total cost of diabetes 
treatment in Europe remained at the level of around 
147 billion USD [10]. It is assumed that one fourth of 
the expenses is allocated to monitoring the level of glu-
cose in patients’ blood, the next 25% is allocated to the 
treatment of diabetes complications, and the remaining 
50% make up the sum of the remaining direct costs con-
nected with doctors’ and nurses’ consultations, costs of 
hospitalization, medical equipment, medication as well 
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as indirect costs (the loss of productivity or efficiency at 
work and absenteeism) [9].
It was possible to make an assessment of costs in-
curred by diabetes per capita per year thanks to the com-
pilations of data on the number of patients with diabe-
tes in 2013 (on the basis of a prevalence coefficient for 
a country), the average costs covering diabetes treatment 
for 2013 and through relating this data to the number of 
people aged between 20–79 (Table I). As data analy-
sis carried out in the developed countries indicates (the 
USA, Denmark, Sweden and France), on average, a sum 
between 5406 USD (France) and 9800 USD (the USA) 
is allocated for the treatment of one person with diabetes, 
while in China these expenses reach merely 333 USD 
(Table I). Relating this data to the total number of the 
population in a given country, it can be observed that the 
highest social burden is noted in the USA (1 068 USD 
per capita), France (405 USD per capita) and Finland 
(402 USD per capita). It should be stressed that in Po-
land, on average 1037 USD is allocated for the treatment 
of one person with diabetes, with the estimated cost bur-
den of 67 USD per inhabitant. The average burden per 
capita for all the analyzed countries amounts to 151 USD 
(per capita) (Table I).
2. Diabetes costs in Poland
Few studies conducted in recent years assess the real 
costs of diabetes treatment in Poland.
In the study on the burden on the Polish society caused 
by diabetes mellitus type 1 and diabetes mellitus type 2, 
the results are shown in the form of public expenses on 
health care among patients with diabetes and also in the 
form of a shortened life span caused by premature death 
and disability resulting from diabetes [12]. It is one of 
very few studies on the global scale which conducted an 
evaluation of the diabetes burden expressed in disabil-
ity adjusted life years – DALY, based on the prospective 
epidemiological research. It has been calculated that in 
1998 the direct costs of diabetes in Poland borne by the 
state budget reached 1937 million PLN, which made up 
9.3% of all the public expenditure incurred on the health 
care at that time (and considering the purchasing power 
of the dollar, it was 1076 million USD PPP). It has also 
been determined that the total number of lost DALYs in 
the analyzed period amounted to 112 584 DALY, repre-
senting over 3% of all DALYs lost in 1998 due to all 
the diseases and afflictions in Poland [12]. In 1998, the 
average costs of treating a patient with diabetes mellitus 
Table I. The total cost of diabetes treatment in the chosen countries in 2013.
Country
Prevalence  
coefficient  
of diabetes for 
a country (%)
Number  
of the population 
(aged 20–79) 
[thous.]
Number  
of person 
with diabetes 
[thous.]
Average cost 
covering diabetes 
treatment
(USD)
Total cost of diabetes 
treatment (USD)  (USD)
Croatia 6.97 3,220.08 224.49 1,378 309,347,220 96.06
Denmark 8.58 4,041.69 346.73 7,272 2,521,420,560 623.85
Russia 10.03 108,928.97 10,924.11 899 9,820,774,890 90.15
Finland 8.85 3,946.2 349.14 4,547 1,587,539,580 402.29
France 7.50 45,009.94 3,374.7 5,406 18,243,628,200 405.32
Greece 7.01 8,336.17 584.6 2,453 1,434,023,800 172.02
Ireland 6.47 3,209.3 207.49 5,598 1,161,529,020 361.92
Germany 11.95 63,281.33 7,559.78 4,718 35,667,042,040 563.62
Poland 6.50 28,907.31 1,879.69 1,037 1,949,238,530 67.43
Czech Republic 9.23 8,190.15 755.7 1,610 1,216,677,000 148.55
Slovak Republic 10.16 4,159.07 422.64 1,621 685,099,440 164.72
Sweden 6.36 6,892.52 438.63 5,806 2,546,685,780 369.48
United Kingdom 6.57 45,307.03 2,974.95 3,994 11,881,950,300 262.25
Italy 7.95 45,637.2 3,626.04 3,501 12,694,766,040 278.16
Mexico 11.77 74,137.43 8,723.42 834 7,275,332,280 98.13
USA 10.90 223,937.51 24,401.77 9,800 239,137,346,000 1067.87
China 9.62 1,023,050.42 98,407.38 333 32,769,657,540 32.03
Indonesia 5.55 154,061.95 8,554.17 143 1,223 246 310 7.93
Japan 7.56 95,304.38 7,203.78 4,054 29,204,124,120 306.43
Brazil 9.04 131,959.75 11,933.58 1,477 17,625,897,660 133.57
Egypt 15.56 48,276.39 7,510.6 176 1,321,865,600 27.38
India 8.56 760,429.73 65,076.36 84 5,466,414,240 7.18
Total − − − − − 151
Source: Own elaboration based on International Diabetes Federation, Diabetes Atlas Update 2013 6th Edition, Brussels, Belgium, 
2013, http://www.idf.org/diabetesatlas/download-book; accessed: 2.07.2014 [10].
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type 1 were 6.4 times higher than in case of patients with 
diabetes mellitus type 2–3 times higher than the aver-
age cost per capita in Poland [13]. Projections relating 
to diabetes costs would amount to 2.46 billion PLN in 
2003, whereas the estimated cost of care for a patient 
with diabetes ranges between 4.9 and 6.8 billion PLN in 
2002 [13]. In turn, projections for 2005 incline towards 
the 22% growth in costs of diabetes treatment, mainly be-
cause of the expected rise in the number of patients [13]. 
One of the studies dealing with the issue of diabetes 
costs in Poland is CODIP (Cost of Diabetes Type 2 in Po-
land) [14]. The aim of the study was to make an overall 
assessment of the total costs of diabetes type 2 treatment 
in Poland in 2002. The assumption and methodology of 
the study were similar to the assumptions of CODE-2 
study, which makes it possible to compare international 
results obtained within the CODIP study. A retrospective, 
multi-centre study (20 centres) of the bottom-up type was 
conducted on a group of 303 patients with diabetes type 2 
(average age 61). As Polish epidemiological data was 
limited, the authors of the study applied randomization 
without stratification in order to choose a test group. The 
aim of the CODIP study was to determine the structure of 
the total costs of diabetes type 2, the overview of current 
strategies of treatment and the evaluation of the impact of 
diabetes complications on costs. The estimated value of 
the resources used by health care and its costs were con-
verted into a period of one year. In direct costs analysis 
three categories were presented: outpatients’ costs, hos-
pital and medication costs, Total direct costs connected 
with diabetes were assessed for around 2.6 billion PLN, 
which made up 8% of all the expenses on health care in 
2002 in Poland. The greatest share in total diabetes costs 
are the costs of hospitalization and pharmacotherapy. Ac-
cording to the authors of the study, the purchase of insu-
lin formulations made up about 2/3 of the costs of hypo-
glycemic agents and the average time of hospitalization 
resulting from complications amounted to 6.2 days. The 
average total direct cost per patient with diabetes type 2 
in Poland in 2012 amounted to 2430 PLN (1185 EUR). 
The dominant cost drivers per patient are anti-diabetic 
drugs (46%) and hospitalization costs (30%) [14]. 
The evaluation of indirect costs of diabetes (using the 
human capital method) carried out additionally within the 
framework of CODIP study indicates that they amount to 
6797 PLN (3316 EUR). The main component of indirect 
costs were costs associated with taking early retirement 
or disability pension (4382 PLN = 2137 EUR), which 
made up about 64% of the total indirect costs. Costs as-
sociated with the third party care were in the second posi-
tion in the structure of indirect costs (34%) [14]. 
The comparison of the results of pharmacotherapeutic 
costs has shown that the patients taking part in the CODIP 
study were over twice more often treated with insulin than 
the patients participating in the CODE-2 study. In com-
parison with CODE-2, the cost of drugs in the CODIP 
study made up a substantial part of the total costs, which 
is probably connected with the relatively high prices of 
drugs in Poland. On the other hand, significantly lower 
expenses connected with hospitalization were observed in 
the CODIP study when compared with CODE-2, which is 
probably due to the underestimation of costs. This situa-
tion may result from a huge debt of Polish hospitals; alter-
natively, it may be the outcome of too low values of unit 
costs. (i.e. day of hospitalization) [14].
Insulin pharmacotherapy makes up 30% of the to-
tal expenditure on diabetes type 2 treatment in Poland, 
and the cost of oral anti-diabetic drugs constitute 17% 
of medical costs and around 4.5% of the total costs. On 
the other hand, in case of diabetes type 1 treatment, the 
dominant role is played by the costs of insulin therapy 
(63%) where hospitalization is responsible for 22% of 
the cost. Insulin therapy has a significant share in the cost 
of diabetes type 2 treatment (46%), similarly as hospital 
treatment (26%). Globally, the cost of insulin therapy 
and the cost of hospitalization have the greatest share 
in the direct costs of diabetes treatment (50% and 25%, 
respectively). In the group of indirect costs, a significant 
role is played by the costs of lowered productivity due to 
early retirement or disability retirement (74%). It should 
be also noted, that the cost of sick leave in the overall in-
direct costs connected with diabetes makes up 11% [15].
It is worth mentioning the significance of very high 
costs generated by diabetes complications, which were 
not taken into account within the framework of the 
CODIP study. It is estimated that the cost of treatment 
of diabetes complications in Poland amounts to around 
0.5 billion PLN which makes up about 25% of the total 
costs (2–2.6 billion PLN). Other sources [15] indicate 
that the cost of treatment of diabetes and its complica-
tions amount to around 6 billion PLN per year in Poland. 
Diabetes complications, type 2 in particular, are the driv-
ers of additional costs of in-patients’ and hospital care 
[15, 16]. It is worth mentioning, that in 2002 the domi-
nant role in overall costs of complications treatment was 
played by the costs of in-patients’ consultations (42%) 
and costs of hospitalization resulting from microan-
giopathic complications (38% and 21%, respectively). 
When it comes to the cost structure of microangiopathic 
complications, the highest costs are observed in connec-
tion with the treatment of kidney complications (54%) 
and ocular complications (37%), whereas in case of 
macroangiopathic complications, over 50% of the costs 
were related with the coronary heart disease [17]. Direct 
costs connected with diabetes complications amounted to 
1.3 billion PLN in 2012, whereas indirect costs amounted 
to almost 1.7 billion PLN [18].
The findings of the research [18] on the costs of diabe-
tes generated between 2004–2009 indicate that the costs 
of health benefits (encompassing basic health care and 
medication) in 2009 went up by 25% in case of diabetes 
type 1 and by 29% in case of diabetes type 2 in compari-
son with 2004. Additionally, it was shown that the costs 
of health benefits (encompassing hospitalization and 
specialist care) doubled in the researched period. In case 
of diabetes type 1, a considerable increase in costs was 
caused by an over 80% rise in the average benefit cost, 
which was mostly connected with the introduction of the 
reimbursement of insulin pumps and the pump equip-
ment for children at that time. It can be assumed that the 
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rise in diabetes type 2 costs was connected with the rise 
in the prevalence of the disease, as the average cost of the 
benefit for 2009 was only 30% higher in comparison with 
2004. Both in case of diabetes type 1 and type 2 the main 
source of additional costs were hospital services. In 2009 
the average cost of health benefits provided to a patient 
with diabetes type 2 in Poland was 414 PLN, and those 
with diagnosed diabetes type 1 – 926 PLN [19]. 
Within the scope of the conducted research, a calcu-
lation of direct as well as indirect costs connected with 
diabetes in Poland was carried out. As no reliable studies 
of this kind referring to the most recent data are available, 
it was considered as appropriate to carry out this type of 
analysis (the exact data were presented in chapters 2.1 
and 2.2).
2.1. The evaluation of direct costs in diabetes treatment  
in Poland from the perspective of the public payer  
(the National Health Fund)
On the basis of the data published by NFZ (the Na-
tional Health Fund) concerning the amount of reimburse-
ment and also information concerning the reimbursed 
formulations placed in announcements by the Health 
Minister, a detailed analysis of the reimbursement ex-
penses was conducted in 2012 and 2013 [20, 21].
It is estimated that from January to December 2012 
the value of the reimbursed drugs applied in the treat-
ment of diabetes (including anti-diabetic drugs, insulin 
and glucose test strips) amounted to over 1.3 billion 
PLN, which made up 19% of the total reimbursement 
sum of around 6.9 billion PLN. In 2013, the amount of 
reimbursement of drugs for diabetes was even higher 
and it amounted to 1.5 billion PLN, similarly as its 
share in the total amount of reimbursement, which was 
21% for 2013 [20, 21].
The highest costs are generated by glucose test strips 
– about 49% (645 million PLN) in 2012 and 52% (793 
million PLN) in 2013. A slightly lower share in total di-
rect cost of diabetes belongs to insulin; 40% (518 million 
PLN) and 38% (583 million PLN), respectively. The low-
est share in total direct costs of 11% (144 million PLN) 
and 10% (155 million PLN) respectively, belongs to anti-
diabetic drugs (Table II, Figure 1).
While conducting a detailed analysis of the individual 
cost categories, it should be emphasized that in 2012 and 
2013 the National Health Fund allocated over 518 mil-
lion PLN and 583 million PLN respectively for the reim-
bursement of insulin, where about 60–62% was the cost 
of human insulin (323 million PLN and 353 million PLN 
respectively), while the remaining 38–40% consisted 
of insulin analogues (195 million PLN and 231 million 
PLN, respectively). The highest reimbursement costs 
among human insulins are incurred by the public payer 
with reference to a mixture of human insulins (65–66% 
of the reimbursement costs of human insulin), whereas 
in case of insulin analogues the highest costs are gen-
erated by mixtures of insulin analogues (47–52% of the 
reimbursement cost of insulin analogues) (Figure 2). In 
a group of oral anti-diabetic drugs, substantial costs are 
generated by biguanides (49–54% of the amount of reim-
bursement of oral anti-diabetic drugs), and then sulfony-
lurea derivatives (40–44% of the reimbursement amount) 
(Figure 3) [20, 21].
According to the National Health Fund (pol. NFZ) 
data, in the compilation of the top 25 substances whose 
Table II. The value of the reimbursed drugs applied in diabetes treatment in 2012 and 2013
No. Category The reimbursement costs (PLN) in 2012 The reimbursement costs (PLN) in 2013
1. Anti-diabetic drugs 143,749,543 155,312,792
1.2 Sulfonylureas 62,609,577 61,912,963
1.2 Biguanides 69,729,083 83,145,399
1.3 Alpha-glucosidase inhibitors 11,410,883 10,254,430
2. Insulins 518,472,407 583,709,379
2.1 Human insulins 323,214,782 352,999,147
2.1.1 Short-acting human insulins 40,475,551 46,822,755
2.1.2 Intermediate-acting human insulins 69,843,724 76,410,157
2.1.3 Premixed human insulins 212,895,508 229,766,235
2.2 Analogue insulins 195,257,625 230,710,231
2.2.1 Long-acting analogue insulins 11,895,070 25,753,189
2.2.2 Rapid-acting analogue insulins 81,189,738 96,166,952
2.2.3 Premixed analogue insulins 102,172,817 108,790,091
3. Glucose test strips 645,254,221 792,809,381
− Total 1,307,476,171 1,531,831,551
Source: Own elaboration based on Komunikaty Departamentu Gospodarki Lekami (DGL). Wartość refundacji cen leków według 
kodów EAN narastająco od początku roku do grudnia 2012 roku [20]; Obwieszczenie Ministra Zdrowia w sprawie wykazu refundo-
wanych leków, środków spożywczych specjalnego przeznaczenia żywieniowego oraz wyrobów medycznych z okresu 2012 roku [21].
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Figure 1. The structure of the reimbursement costs dedicated to diabetes treatment in 2012 and 2013
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Source: Own elaboration on the basis of the National Health Fund data: Komunikaty Departamentu Gospodarki Lekami (DGL). 
Wartość refundacji cen leków według kodów EAN narastająco od początku roku do grudnia 2012 roku [20]; Obwieszczenie Mi-
nistra Zdrowia w sprawie wykazu refundowanych leków, środków spożywczych specjalnego przeznaczenia żywieniowego oraz 
wyrobów medycznych z okresu 2012 roku [21]. 
Figure 2. The structure of reimbursement costs for human insulin and insulin analogues in 2012 and 2013
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Source: Own elaboration on the basis of the National Health Fund data: Komunikaty Departamentu Gospodarki Lekami (DGL). 
Wartość refundacji cen leków według kodów EAN narastająco od początku roku do grudnia 2012 roku [20]; Obwieszczenie Mi-
nistra Zdrowia w sprawie wykazu refundowanych leków, środków spożywczych specjalnego przeznaczenia żywieniowego oraz 
wyrobów medycznych z okresu 2012 roku [21]. 
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reimbursement is the most costly (about 40% of the over-
all reimbursement amount), insulin is in the third position 
(5.26% of the overall reimbursement amount).
When analyzing the direct cost of diabetes treatment, 
attention should be paid to the issue of undiagnosed dia-
betes, which is undoubtedly a serious social and health 
problem. It is estimated that 609.02 thousand of people 
aged 20–79 in Poland do not realize that they are affected 
by diabetes [10].The analysis of type MZ-11 reports, 
which are directly passed to the head office of the Nation-
al Health Fund from regional branches has shown that the 
detection rate of diabetes is steadily increasing and so is 
the number of patients diagnosed with diabetes. Diabetes 
detection rate growth will be translated into increasing 
expenditure for its treatment in the following years as 
well as the decrease in the expenditure for complications 
treatment (because of its early detection).
2.2. The evaluation of indirect costs of diabetes in Poland
So far research on indirect costs connected with dia-
betes in the Polish conditions has been conducted on the 
basis of the National Health Fund and Social Insurance 
(pol. ZUS) data so far. It should be stressed, that because 
of the implementation of the system solutions, the num-
ber of granted disability pensions is falling down every 
year. The number of decisions on incapacity for work due 
to diabetes has also fallen down in case of diabetes [18]. 
On the basis of the report by Leon Koźminski Academy, 
(ALK) in Warsaw [19] it has been observed that between 
2004–2009 the decrease rate for decisions on incapacity 
for work among people with diabetes is lower than for 
the whole population. In the analyzed years, on the other 
hand, the rise in the number of the granted rehabilitation 
services and sickness benefits has been observed. The 
ALK report indicates that indirect costs make up almost 
50% of the cost of diabetes.
On the basis of the data provided by the Social Insur-
ance, the Department of Statistics and Actuarial Projec-
tions, in numbers of [22]:
• sick absences in 2012 due to illness of people insured 
in ZUS in the order of disease entity;
• first-time medical decisions by Social Insurance  cer-
tifying physicians issued in 2012 qualifying for reha-
bilitation services by gender and disease entity (the 
value used to define short-term disability);
• first-time medical decisions by ZUS certifying phy-
sicians issued in 2012 qualifying for rehabilitation 
services with the simultaneous need for remedial 
rehabilitation by gender, the projected period of di-
sability for work and disease entity (the value used to 
determine short-term disability);
• first-time and renewed medical decisions establishing 
complete inability to work issued by ZUS certifying 
physicians to people applying for a social assistance 
pension, by gender and disease entity (the value used 
to determine long-term disability, i.e. pensions),
indirect costs of insulin-dependent diabetes (type 1) and 
insulin-independent diabetes (type 2) were assessed in 
Poland in 2012.
Figure 3. The structure of reimbursement costs for anti-diabetic drugs in 2012 and 2013
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Source: Own elaboration on the basis of the National Health Fund data: Komunikaty Departamentu Gospodarki Lekami (DGL). 
Wartość refundacji cen leków według kodów EAN narastająco od początku roku do grudnia 2012 roku [20]; Obwieszczenie Mi-
nistra Zdrowia w sprawie wykazu refundowanych leków, środków spożywczych specjalnego przeznaczenia żywieniowego oraz 
wyrobów medycznych z okresu 2012 roku [21]. 
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In the calculations of indirect costs, additional infor-
mation was used – gross value added (GVA) per employ-
ee in 2012, remuneration per employee in 2012 and gross 
domestic product (GDP) per capita in 2012. The infor-
mation above was obtained from the Central Statistical 
Office (www.stat.gov.pl). The Table III presents a break-
down of figures described above for diabetes type  1 and 
type 2 in 2012.
In 2012 one sickness absence of an employee with 
diabetes type 1 or 2 generated the average cost of pro-
ductivity loss of 1771 PLN or 1585 PLN, respectively. 
A short-term cost in the form of one entitlement to 
a rehabilitation service in 2012 amounted to 17 249 PLN, 
both in case of diabetes type 1 and 2. The cost is gener-
ated by patients who need rehabilitation and is the same, 
regardless the type of diabetes, because in both cases the 
average length of rehabilitation is the same (5 months) 
and thus the cost of productivity loss also remains the 
same [22]. In 2012 the highest unit costs were generated 
by decisions about permanent disability to work (dis-
ability pensions). The cost of one medical decision (one 
disability pension) in case of patients with diabetes type 
1 and 2 amounted to 41 398 PLN [22].
The total indirect costs of diabetes type 1 and 2 
in Poland in 2012 amounted to 59 013912 PLN and 
66 597 701 PLN, respectively. The greatest share 
in indirect costs in case of diabetes type 1 in Poland in 
2012 belongs to sickness absence. A considerable share 
in indirect costs was also observed in case of medical 
decisions about long-term disability to work (disability 
pension). The entitlements to rehabilitation services is-
sued to patients with diabetes type 1 in Poland in 2012 
were responsible for over 11% of the total indirect costs 
(Figure 4). The case of diabetes type 2 presents itself 
in a slightly different way. In 2012, very few decisions 
about long-term disability to work were issued to patients 
with diabetes type 2; thus the cost of these decisions 
amounted to just a little below 1% of the total indirect 
costs. A slightly higher number of people with diabetes 
type 2 received short-term services in the form of enti-
tlement to rehabilitation services; however, their costs 
did not exceed a 5% share in total indirect costs. 95% of 
indirect costs of diabetes type 2 in Poland in 2012 were 
made up of the cost of sickness absence (Figure 5) [22].
Summary
The conducted study overview concerned the evalu-
ation of the total direct and indirect costs of diabetes 
treatment – in Poland and world-wide. Research findings 
indicate that the prevalence of this disease is associated 
with high costs burdening the societies in individual 
countries. It is estimated that the treatment of diabetes in 
2013 absorbed 548 billion USD, which makes up about 
11% of the total expenditure on health care all around the 
world [10]. 
Studies concentrating on costs of a disease, indirect 
cost in particular, currently constitute a serious challenge 
for decision-makers, e.g. in the health service or for spe-
cialists in public health. Studies concentrating on direct 
costs are simpler to conduct as gathering data is easy and 
popular; therefore a number of publications of this type 
about diabetes are available. On the other hand, indirect 
cost analysis is more difficult to carry out, mainly be-
cause of the lack of clear-cut, comprehensive data sourc-
es and because of difficulties with their measurement. 
Table III. The cost of sickness absence and short and long-term disability to work for patients with diabetes type 1 and 2
Parameter Category
Costs in 2012 
Diabetes type 1 Diabetes type 2
Sickness absence
Number of sick leaves 20,368 39,753
Number of years 871 1,522
GDP valuea 36,065,620 62,992,625
Cost per 1 sick leaveb 1,771 PLN 1,585 PLN
Short-term disability to work 
Number of permissions for rehabilitation benefits 380c 173c
Average length of rehabilitation benefit [months] 5 5
Number of yearsd 158 72
GDP valuea 6,554,683 2,980,656
Cost per 1 short-term benefite 17,249 PLN 17,249 PLN
Long-term disability to work  
(disability pension)
Number of decisions of total disability to work 396 15
GDP valuea 16,393 608 620,970
Cost per one decisionf 41,398 PLN 41,398 PLN
a calculated as number of years multiplied by GDB per capita (41 398 PLN); b calculated as quotient of GDP value and number of sick leaves; 
c including 5 and 2 permissions for rehabilitation benefit with simultaneous need of therapeutic rehabilitation in case of diabetes type 1 and 2, 
respectively; d calculated as number of permissions for rehabilitation benefits multiplied by an average length of benefit in years; e calculated as 
quotient of GDP value and number of permissions; f calculated as quotient of GDP value and number of citizens (GDP per capita). 
Source: Own elaboration based on Zakład Ubezpieczeń Społecznych (ZUS) – Portal Statystyczny ZUS, http://www.psz.zus.pl/; 
accessed: 20.07.2014 [22].
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Therefore, there are no reliable publications dealing with 
indirect costs; indirect costs of diabetes in Poland in par-
ticular. The chosen HCA method estimates maximum 
costs but it does not take into account the unemployment 
rate or marginal efficiency.
As presented in the SMG/KRC report, “Diabetes treat-
ment and costs in Poland” [23], the expenses allocated to 
diabetes treatment in Poland are definitely lower (almost 
3 times) than in countries of the so-called “old European 
Union”. Analyzing carefully the expenses connected with 
diabetes in Poland, we can see that the highest share be-
longs to costs of hospitalization, in-patients’ treatment 
and pharmacotherapy [14]. The structure of funds allo-
cated for diabetes treatment in Poland is similar to the 
structure of expenses typical to the developing countries 
and it differs from the one which can be observed in mod-
ern European countries. Additionally, taking into account 
indirect costs connected with diabetes in the developed 
countries, the direct investment in controlling diabetes 
does not exceed 25% of the total costs connected with 
diabetes. On the basis of the identified studies’ findings 
it can be assumed that economic growth in Poland will 
contribute to the changes in the health care system, bring-
ing the rise in financial investment dedicated to hospital 
and in-patients’ are (i.e. the rise in doctors’, nurses’ and 
medical staff salaries to reduce immigration). It should 
be also stressed that in the subsequent years and decades, 
the number of patients with diabetes in Poland will grow 
(it is estimated that in 2035 the number of patients with 
diabetes world-wide will rise from 382 million to almost 
592 million [10], which in consequence will additionally 
burden the budget with costs of medical care, in particu-
lar within the scope of complications treatment, and will 
bring the rise of indirect costs generated by complica-
tions, the so-called costs connected with sickness absence 
at work, reduced productivity, lowered standard of life, 
reduced productivity of patients’ carers or disability pen-
sions which at present absorb a significant part of the 
Polish GDP [23].
The analysis of the reimbursement expenses of the 
National Health Fund has proved that the reimburse-
ment of drugs in diabetes therapy amounted to 1.3 bil-
lion PLN in 2012 and 1.5 billion PLN in 2013. These 
figures made up 19% and 21%, respectively of the total 
Figure 4. Individual categories of indirect costs of diabetes type 1 in Poland in 2012
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Source: Own elaboration based on Zakład Ubezpieczeń Społecznych (ZUS) – Portal Statystyczny ZUS, http://www.psz.zus.pl/; 
accessed: 20.07.2014 [22].
Figure 5. Individual categories of indirect costs of diabetes type 2 in Poland in 2012
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Source: Own elaboration based on Zakład Ubezpieczeń Społecznych (ZUS) – Portal Statystyczny ZUS, http://www.psz.zus.pl/; 
accessed: 20.07.2014 [22].
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NHF expenses allocated for the reimbursement of drugs 
and medical products in Poland. It should be also high-
lighted that the highest costs (almost half of them) are 
generated by the reimbursement of glucose test strips 
and insulin (mostly human insulin) [20, 21]. In turn, the 
analysis of indirect costs of diabetes has indicated that 
in 2012 these costs amounted to almost 60 million PLN 
in case of diabetes type 1 and over 66 million PLN in 
case of diabetes type 2. What is more, sickness absence 
had the highest share in indirect costs in case of diabe-
tes type 1. A significant share in indirect costs was also 
observed in case of medical decisions about long-term 
disability to work (disability pension). In 2012, 95% of 
indirect costs of diabetes type 2 in Poland consisted of 
the cost of sickness absence [22]. 
The conclusions presented within the above research 
review, especially those referring to Poland, should to 
a greater extent draw the attention of decision-makers in 
health care as well as the public opinion. A number of 
steps should be taken to try and reduce diabetes type 2 
prevalence, to carry out earlier and better diagnosis as 
well as to reduce  and delay the onset of diabetes compli-
cations. To achieve this aim, effective health and educa-
tion programmes should be implemented, while patients 
should be provided with professional care and access to 
modern therapeutic methods.
Note
1 Purchasing Power Parity – a way of expressing the curren-
cy of one country in the currency of another country. It defines 
a relation between the level of prices in one country to the level 
of prices in another country.
References
1. Sieradzki J., Choroby układu wewnątrzwydzielniczego, in: 
Gajewski P. (ed.), Interna Szczeklika, Medycyna Praktycz-
na, Kraków 2013: 1353–1376.
2.  IDF Diabetes Atlas, http://www.diabetesatlas.org/re-
sources/2014-atlas.html; accessed: 20.07.2014.
3. Hermanowski T., Szacowanie kosztów społecznych choroby 
i wpływu stanu zdrowia na aktywność zawodową i wydaj-
ność pracy, Wolters Kluwer, Warszawa 2013.
4. Raport na zlecenie Związku Pracodawców Innowacyjnych 
Firm Farmaceutycznych INFARMA, Metodyka pomiaru 
kosztów pośrednich w polskim systemie ochrony zdrowia, 
Warszawa 2013.
5. Gajewski P., Jaeschke R., Brożek J. Podstawy EBM, czyli 
medycyny opartej na danych naukowych dla lekarzy i stu-
dentów medycyny, Medycyna Praktyczna, Kraków 2008.
6. Orlewska E., Nowakowska E., Farmakoekonomika dla 
studentów i absolwentów Akademii Medycznych, Wydaw-
nictwo Akademii Medycznej im. Karola Marcinkowskiego 
w Poznaniu, Poznań 2004: 26–48.
7. Kissimova-Skarbek K., Koszty obciążenia chorobami, in: 
Golinowska S. (ed.), Od ekonomii do ekonomiki zdrowia. 
Podręcznik ekonomiki zdrowia, PWN, Warszawa 2015: 
354–391.
8. Drummond M., Stoddart G., Torrance G., Methods for the 
Economic Evaluation of Health Care Programmes, Oxford 
Medical Publications, Oxford 1987.
9. International Diabetes Federation, Diabetes Atlas Update 
2012, 5th Edition, Brussels, Belgium, 2012, http://www.
idf.org/diabetesatlas/5e/Update201211.03.2014; accessed: 
20.07.2014.
10. International Diabetes Federation, Diabetes Atlas Update 
2013 6th Edition, Brussels, Belgium, 2013, http://www.idf.
org/diabetesatlas/download-book; accessed: 2.07.2014.
11. Zhang Y., Dall TM., Mann SE. et al., The economic costs 
of undiagnosed diabetes, “Popul. Health Manag.” 2009; 
12 (2): 95–101. 
12. Kissimova-Skarbek K., Pach D., Płaczkiewicz E., Szurkow-
ska M., Szybiński Z., Ocena ekonomicznego obciążenia 
cukrzycą społeczeństwa Polski, “Polskie Archiwum Medy-
cyny Wewnętrznej” 2001; 106, 3 (9): 867–875.
13. Kissimova-Skarbek K., Ekonomika cukrzycy – wybrane za-
gadnienia metodologiczne. “Zeszyty Naukowe IZP” 2007: 
V (1–2): 46–64.
14. Kinalska I., Niewada M., Głogowski C. et al., Koszty cuk-
rzycy typu 2 w Polsce (badanie CODIP), “Diabetologia 
Praktyczna” 2004; 5 (1): 1–58. 
15. Kawalec P., Kielar M., Pilc A., Koszty leczenia cukrzycy 
typu 1 i 2 w Polsce, “Diabetologia Praktyczna” 2006; 7 (5): 
287–294. 
16.  Cukrzyca, Ukryta pandemia. Sytuacja w Polsce, Edycja 
2013. 
17. Kawalec P., Pilc P., Analiza kosztów leczenia powikłań cuk-
rzycy poniesionych przez płatnika w Polsce w 2002 roku, 
“Diabetologia Praktyczna” 2004; 5 (1): 9–14.
18. Leśniowska J., Schubert A., Wojna M. et al., Costs of diabe-
tes and its complications in Poland, “Eur. J. Health Econ.” 
2014; 15 (6): 653-60.
19. Furman R., Struktura kosztów cukrzycy. Warszawa (na pod-
stawie Raportu przygotowanego przez Akademię Leona 
Koźmińskiego) 2011.
20. Komunikaty Departamentu Gospodarki Lekami (DGL). 
Wartość refundacji cen leków według kodów EAN narasta-
jąco od początku roku do grudnia 2012 roku.
21. Obwieszczenie Ministra Zdrowia w sprawie wykazu re-
fundowanych leków, środków spożywczych specjalnego 
przeznaczenia żywieniowego oraz wyrobów medycznych 
z okresu 2012 roku.
22. Zakład Ubezpieczeń Społecznych (ZUS) – Portal Staty-
styczny ZUS, http://www.psz.zus.pl/; accessed: 20.07.2014.
23. SMG/KRC, Leczenie i koszty cukrzycy w Polsce, 2007.
